Chidley, Christopher http://orcid.org/0000-0002-8212-3148
Darnell, Alicia M.
Gaudio, Benjamin L.
Lien, Evan C.
Barbeau, Anna M.
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Funding for this research was provided by:
Jane Coffin Childs Memorial Fund for Medical Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA014051, R35-CA242379, U54-CA225088)
Lustgarten Foundation
Ludwig Institute for Cancer Research
MIT Center for Precision Cancer Medicine
Termeer Foundation
Article History
Received: 23 May 2023
Accepted: 7 March 2024
First Online: 11 April 2024
Competing interests
: M.G.V.H. is a scientific advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Auron Therapeutics and Droia Ventures. P.K.S. is a co-founder and member of the BOD of Glencoe Software, a member of the BOD of Applied Biomath and a member of the SAB of RareCyte, NanoString and Montai Health, and a consultant for Merck. None of these relationships has influenced the content of this manuscript. The other authors declare no competing interests.